Across TCGA pan-cancer cohorts, METTL9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated METTL9 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher METTL9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated METTL9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where METTL9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.481	0.772	.001	36	view →
CCRCC	OS	Median	IV	0.123	0.785	.009	23	view →
PDAC	DFS	Quartile	III,IV	0.302	0.934	.024	12	view →
UCEC	DFS	Median	All	1.000	0.936	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: METTL9 tumor-vs-normal RNA expression · all METTL9 data types